Press Releases

Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s Cross neighborhood LONDON , March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq:

SALT LAKE CITY , March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Disease Day event at its headquarters on February 29 and virtually in partnership with Alliance to

SALT LAKE CITY , March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media and Telecom Conference –

Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the near-term In-licensed a program (Target Epsilon) that emerged from our fibrosis collaboration with

SALT LAKE CITY , Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2023 financial results on Tuesday,

Launches Fellowship Grant Opportunity for Early Career Entrepreneurs SALT LAKE CITY , Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altitude Lab today announced that its incubating startups raised over $120M in early-stage funding since commencing operations in 2020.

Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug discovery tasks and orchestrate both wet-lab and dry-lab components of the Recursion OS using a natural

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed

SALT LAKE CITY , Jan. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris Gibson , Ph.D., Co-founder and CEO, will help kick off the 42nd Annual J.P.

Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. KYIV, Ukraine and SALT LAKE CITY , Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding